Beyond the Scale: The Economic Power of GLP-1 Therapies

GLP-1 therapies are reshaping obesity treatment, delivering meaningful weight loss, reducing the risk of comorbidities like type 2 diabetes and cardiovascular disease, and unlocking billions in potential healthcare savings. Widespread use could also improve worker productivity, boost economic output, and lessen the ripple effects of obesity on individuals and the economy at large.

But current policy hasn’t kept pace. Lawmakers need to prioritize continued investment in GLP-1 research, make sure these treatments are accessible to everyone who needs them, and update CBO modeling with dynamic scoring to capture the true economic gains of reducing obesity.

Join ITIF on Capitol Hill for a timely discussion on how GLP-1 therapies can transform health and economic outcomes—and what policymakers should do to maximize their benefits.

Questions for the speakers? Ask on Slido.